Linked Data API

Show Search Form

Search Results

1058750
registered interest false more like this
date less than 2019-02-11more like thismore than 2019-02-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading UK Antimicrobial Resistance Diagnostics Collaborative more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what (a) representations his Department has received on the work of the UK Antimicrobial Resistance (AMR) Diagnostics Collaborative and (b) discussions have taken place between his Department and members of that group; what the timetable is for the publication of the AMR Diagnostics Collaborative's report; and (c) if he will make a statement. more like this
tabling member constituency Ealing, Southall more like this
tabling member printed
Mr Virendra Sharma more like this
uin 219373 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-14more like thismore than 2019-02-14
answer text <p>Over the last five years, implementation of the United Kingdom antimicrobial resistance (AMR) strategy has been overseen and driven by a cross-Government High Level Steering Group, chaired by the Chief Medical Officer for England.</p><p> </p><p>Professor Dame Sue Hill, Chief Scientific Officer for NHS England, leads work to deliver the Government’s ambitions for diagnostics as part of the strategy. NHS England established the UK AMR Diagnostics Collaborative to support delivery of the United Kingdom’s diagnostics ambitions for AMR. The Collaborative has played a valuable role in developing the diagnostics elements of the new UK five-year national action plan on AMR, published in January this year.</p><p> </p><p>The Department continues to work closely with the UK AMR Diagnostics Collaborative, which currently has no plans to publish a report.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2019-02-14T17:44:29.493Zmore like thismore than 2019-02-14T17:44:29.493Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
1604
label Biography information for Mr Virendra Sharma more like this
1058752
registered interest false more like this
date less than 2019-02-11more like thismore than 2019-02-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Drugs: Death more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the implications for his Department's policies of the findings of the National Aids Trust report, Drug-Related Deaths in England, published by the National Aids Trust, published on 5 February 2019; and if he will make a statement. more like this
tabling member constituency Easington more like this
tabling member printed
Grahame Morris more like this
uin 219400 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-14more like thismore than 2019-02-14
answer text <p>No formal assessment has been made of the National AIDS Trust report however officials will consider its findings in the development of future drugs policy. The Government is concerned by the number of drug-related deaths and is supporting local areas to develop a more joined up approach to commissioning and delivering the range of services that are essential to supporting recovery and preventing drug-related deaths.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2019-02-14T17:45:27.307Zmore like thismore than 2019-02-14T17:45:27.307Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
3973
label Biography information for Grahame Morris more like this
1058753
registered interest false more like this
date less than 2019-02-11more like thismore than 2019-02-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading NHS: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, with reference to the proposed amendments to the Human Medicines Regulation 2012, what treatment areas will be excluded from the serious shortage protocol for reasons of patient safety; and if he will publish a list of medicines and formulations that will be excluded as a result. more like this
tabling member constituency Sunderland Central more like this
tabling member printed
Julie Elliott more like this
uin 219427 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-14more like thismore than 2019-02-14
answer text <p>A Serious Shortage Protocol is an additional tool to manage and mitigate medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>As the explanatory memorandum of the amending Statutory Instrument acknowledges, protocols for therapeutic or generic equivalents will not be suitable for all medicines and patients. For example, such protocols would not be suitable for medicines that need to be prescribed by brand for clinical reasons, such as biological medicines. In these cases, patients would always be referred to the prescriber for any decision about their treatment before any therapeutic or generic alternative is supplied.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2019-02-14T17:35:25.567Zmore like thismore than 2019-02-14T17:35:25.567Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4127
label Biography information for Julie Elliott more like this
1058754
registered interest false more like this
date less than 2019-02-11more like thismore than 2019-02-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading NHS: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, with reference to the Human Medicines (Amendment) Regulation 2019, what the system will be by which clinicians will be able to indicate whether or not an alternative (a) quantity, (b) strength, and (c) pharmaceutical form of medicine can be dispensed in line with the protocol; and how this system will be applied to regular repeat prescriptions. more like this
tabling member constituency Sunderland Central more like this
tabling member printed
Julie Elliott more like this
uin 219428 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-14more like thismore than 2019-02-14
answer text <p>A Serious Shortage Protocol is an additional tool to manage and mitigate medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective. It can only be issued by Ministers and would only be introduced in the case of a serious shortage, if it would help manage the supply situation and if clinicians think it is appropriate, after discussion with the manufacturer and/or marketing authorisation holder.</p><p> </p><p>Any protocol would need to set out what alternative quantity, pharmaceutical form, strength, therapeutic equivalent or generic equivalent can be supplied. Supply in accordance with a protocol can only be made if the protocol is in date when a prescription is presented for dispensing, whether that prescription is an acute or a repeat prescription. If appropriate, the protocol could stipulate that it does not apply to a certain type of prescription.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2019-02-14T17:47:44.153Zmore like thismore than 2019-02-14T17:47:44.153Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4127
label Biography information for Julie Elliott more like this
1058800
registered interest false more like this
date less than 2019-02-11more like thismore than 2019-02-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Pharmacy: Public Health more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of nationally commissioning more public health services through community pharmacy. more like this
tabling member constituency Rother Valley more like this
tabling member printed
Sir Kevin Barron more like this
uin 219278 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-14more like thismore than 2019-02-14
answer text <p>The Government has been clear that it wants to change the focus of the health and care system onto prevention and Ministers have also set out an ambition for local pharmacies to play a stronger role in helping people stay well in the community. The Department has committed to publishing a Green Paper on prevention that will set out how these plans will be achieved in more detail. An assessment specifically focusing on the potential merits of nationally commissioning more public health services through community pharmacy has not been undertaken.</p><p>An updated list of the 1,413 pharmacies found to be eligible for the pharmacy access scheme was published in January 2018, this is publicly available and can be found at the following link:</p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf</a></p><p>A small proportion of the pharmacies eligible for the scheme will not receive a payment because they do not meet the payment criteria as set out in the Drug Tariff. This means their income in 2016/17 is greater than their 2015/16 income less a 1% efficiency saving, and/or their estimated income in 2017/18 and 2018/19 is greater than their 2015/16 income less a 3% efficiency saving. The number and proportion of pharmacies on the scheme in receipt of a payment, for each year that the scheme has been running, is set out in the following table.</p><table><tbody><tr><td><p> </p></td><td><p>Total number of eligible pharmacies</p></td><td><p>Total number of pharmacies receiving zero payments</p></td><td><p>Total number of pharmacies in receipt of payment</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,402</p></td><td><p>47 (3%)</p></td><td><p>1,355 (97%)</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,415<sup><sup>[1]</sup></sup></p></td><td><p>57 (4%)</p></td><td><p>1,358 (96%)</p></td></tr></tbody></table><p><sup><sup><br>[1]</sup></sup>Two additional pharmacies have been accepted on to the scheme since the publication of the updated list. This explains the difference in the figures of 1,413 and 1,415 for 2017/18.</p><p>The fees and allowances paid under the Community Pharmacy Contractual Framework (CPCF) for the provision of essential services, including dispensing, provided by community pharmacies each year from April 2015 to March 2018 are detailed in the following table, based on data provided by NHS England. The structure of fees and allowances does not allow payments just for dispensing to be isolated. These payments do not include the medicine margin that community pharmacies earn as part of the payment for essential services, which is paid through reimbursement within the drugs’ bill.</p><p>Enhanced services are locally commissioned. As such they are funded outside of the national CPCF and the Department does not hold the information sought.</p><table><tbody><tr><td><p>Time period</p></td><td><p>Total essential services funding<sup>2</sup> /£</p></td><td><p>Total national CPCF funding (essential and advanced services) less medicines margin/ £</p></td><td><p>Funding for essential services as a proportion of total national CPCF funding (essential and advanced services) less medicines margin/ %</p></td></tr><tr><td><p>2015/16</p></td><td><p>1,881,828,149</p></td><td><p>2,000,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,769,216,586</p></td><td><p>1,887,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,668,141,583</p></td><td><p>1,792,000,000</p></td><td><p>93</p></td></tr></tbody></table><p><sup><br>2</sup>This comprises the fees and allowances paid under Part IIIA: Professional Fees (Pharmacy Contractors) and Part VIA: Payment for Essential Services (Pharmacy Contractors) of the Drug Tariff, and through the Quality Payment Scheme and Pharmacy Access Scheme. This does not include medicines margin.</p><p>Within the NHS Long Term Plan, Government has committed to expanding the number of pharmacists in Primary Care Networks. These pharmacists are well placed to work alongside the wider medical team to optimise the use of medicines, promote medicines adherence and improve the clinical and cost effectiveness of prescribed medications. Identifying and supporting patients on complex polypharmacy and those with long term conditions necessitating repeat prescriptions will form an important part of their role. Alongside this, in August 2018, NHS England, announced plans for a new pilot scheme, with investment of £1 million from the Pharmacy Integration Fund to develop system leadership within pharmacy across all settings. These pharmacy leaders will set the vision to systematically tackle medicines optimisation priorities for the local population within GP Network and Integrated Care System foot prints, further supporting medicines adherence, and in turn reducing medicines wastage.</p><p> </p><p> </p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN
219279 more like this
219280 more like this
219281 more like this
question first answered
less than 2019-02-14T17:46:27.253Zmore like thismore than 2019-02-14T17:46:27.253Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
392
label Biography information for Sir Kevin Barron more like this
1058801
registered interest false more like this
date less than 2019-02-11more like thismore than 2019-02-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Pharmacy: Finance more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will list each pharmacy in receipt of funding from the Pharmacy Access Scheme in each year since the establishment of that scheme. more like this
tabling member constituency Rother Valley more like this
tabling member printed
Sir Kevin Barron more like this
uin 219279 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-14more like thismore than 2019-02-14
answer text <p>The Government has been clear that it wants to change the focus of the health and care system onto prevention and Ministers have also set out an ambition for local pharmacies to play a stronger role in helping people stay well in the community. The Department has committed to publishing a Green Paper on prevention that will set out how these plans will be achieved in more detail. An assessment specifically focusing on the potential merits of nationally commissioning more public health services through community pharmacy has not been undertaken.</p><p>An updated list of the 1,413 pharmacies found to be eligible for the pharmacy access scheme was published in January 2018, this is publicly available and can be found at the following link:</p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf</a></p><p>A small proportion of the pharmacies eligible for the scheme will not receive a payment because they do not meet the payment criteria as set out in the Drug Tariff. This means their income in 2016/17 is greater than their 2015/16 income less a 1% efficiency saving, and/or their estimated income in 2017/18 and 2018/19 is greater than their 2015/16 income less a 3% efficiency saving. The number and proportion of pharmacies on the scheme in receipt of a payment, for each year that the scheme has been running, is set out in the following table.</p><table><tbody><tr><td><p> </p></td><td><p>Total number of eligible pharmacies</p></td><td><p>Total number of pharmacies receiving zero payments</p></td><td><p>Total number of pharmacies in receipt of payment</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,402</p></td><td><p>47 (3%)</p></td><td><p>1,355 (97%)</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,415<sup><sup>[1]</sup></sup></p></td><td><p>57 (4%)</p></td><td><p>1,358 (96%)</p></td></tr></tbody></table><p><sup><sup><br>[1]</sup></sup>Two additional pharmacies have been accepted on to the scheme since the publication of the updated list. This explains the difference in the figures of 1,413 and 1,415 for 2017/18.</p><p>The fees and allowances paid under the Community Pharmacy Contractual Framework (CPCF) for the provision of essential services, including dispensing, provided by community pharmacies each year from April 2015 to March 2018 are detailed in the following table, based on data provided by NHS England. The structure of fees and allowances does not allow payments just for dispensing to be isolated. These payments do not include the medicine margin that community pharmacies earn as part of the payment for essential services, which is paid through reimbursement within the drugs’ bill.</p><p>Enhanced services are locally commissioned. As such they are funded outside of the national CPCF and the Department does not hold the information sought.</p><table><tbody><tr><td><p>Time period</p></td><td><p>Total essential services funding<sup>2</sup> /£</p></td><td><p>Total national CPCF funding (essential and advanced services) less medicines margin/ £</p></td><td><p>Funding for essential services as a proportion of total national CPCF funding (essential and advanced services) less medicines margin/ %</p></td></tr><tr><td><p>2015/16</p></td><td><p>1,881,828,149</p></td><td><p>2,000,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,769,216,586</p></td><td><p>1,887,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,668,141,583</p></td><td><p>1,792,000,000</p></td><td><p>93</p></td></tr></tbody></table><p><sup><br>2</sup>This comprises the fees and allowances paid under Part IIIA: Professional Fees (Pharmacy Contractors) and Part VIA: Payment for Essential Services (Pharmacy Contractors) of the Drug Tariff, and through the Quality Payment Scheme and Pharmacy Access Scheme. This does not include medicines margin.</p><p>Within the NHS Long Term Plan, Government has committed to expanding the number of pharmacists in Primary Care Networks. These pharmacists are well placed to work alongside the wider medical team to optimise the use of medicines, promote medicines adherence and improve the clinical and cost effectiveness of prescribed medications. Identifying and supporting patients on complex polypharmacy and those with long term conditions necessitating repeat prescriptions will form an important part of their role. Alongside this, in August 2018, NHS England, announced plans for a new pilot scheme, with investment of £1 million from the Pharmacy Integration Fund to develop system leadership within pharmacy across all settings. These pharmacy leaders will set the vision to systematically tackle medicines optimisation priorities for the local population within GP Network and Integrated Care System foot prints, further supporting medicines adherence, and in turn reducing medicines wastage.</p><p> </p><p> </p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN
219278 more like this
219280 more like this
219281 more like this
question first answered
less than 2019-02-14T17:46:27.3Zmore like thismore than 2019-02-14T17:46:27.3Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
392
label Biography information for Sir Kevin Barron more like this
1058802
registered interest false more like this
date less than 2019-02-11more like thismore than 2019-02-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Pharmacy: Expenditure more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how much and proportion of pharmacy funding has been spent on (a) dispensing and (b) enhanced services in each year since 2015-16. more like this
tabling member constituency Rother Valley more like this
tabling member printed
Sir Kevin Barron more like this
uin 219280 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-14more like thismore than 2019-02-14
answer text <p>The Government has been clear that it wants to change the focus of the health and care system onto prevention and Ministers have also set out an ambition for local pharmacies to play a stronger role in helping people stay well in the community. The Department has committed to publishing a Green Paper on prevention that will set out how these plans will be achieved in more detail. An assessment specifically focusing on the potential merits of nationally commissioning more public health services through community pharmacy has not been undertaken.</p><p>An updated list of the 1,413 pharmacies found to be eligible for the pharmacy access scheme was published in January 2018, this is publicly available and can be found at the following link:</p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf</a></p><p>A small proportion of the pharmacies eligible for the scheme will not receive a payment because they do not meet the payment criteria as set out in the Drug Tariff. This means their income in 2016/17 is greater than their 2015/16 income less a 1% efficiency saving, and/or their estimated income in 2017/18 and 2018/19 is greater than their 2015/16 income less a 3% efficiency saving. The number and proportion of pharmacies on the scheme in receipt of a payment, for each year that the scheme has been running, is set out in the following table.</p><table><tbody><tr><td><p> </p></td><td><p>Total number of eligible pharmacies</p></td><td><p>Total number of pharmacies receiving zero payments</p></td><td><p>Total number of pharmacies in receipt of payment</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,402</p></td><td><p>47 (3%)</p></td><td><p>1,355 (97%)</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,415<sup><sup>[1]</sup></sup></p></td><td><p>57 (4%)</p></td><td><p>1,358 (96%)</p></td></tr></tbody></table><p><sup><sup><br>[1]</sup></sup>Two additional pharmacies have been accepted on to the scheme since the publication of the updated list. This explains the difference in the figures of 1,413 and 1,415 for 2017/18.</p><p>The fees and allowances paid under the Community Pharmacy Contractual Framework (CPCF) for the provision of essential services, including dispensing, provided by community pharmacies each year from April 2015 to March 2018 are detailed in the following table, based on data provided by NHS England. The structure of fees and allowances does not allow payments just for dispensing to be isolated. These payments do not include the medicine margin that community pharmacies earn as part of the payment for essential services, which is paid through reimbursement within the drugs’ bill.</p><p>Enhanced services are locally commissioned. As such they are funded outside of the national CPCF and the Department does not hold the information sought.</p><table><tbody><tr><td><p>Time period</p></td><td><p>Total essential services funding<sup>2</sup> /£</p></td><td><p>Total national CPCF funding (essential and advanced services) less medicines margin/ £</p></td><td><p>Funding for essential services as a proportion of total national CPCF funding (essential and advanced services) less medicines margin/ %</p></td></tr><tr><td><p>2015/16</p></td><td><p>1,881,828,149</p></td><td><p>2,000,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,769,216,586</p></td><td><p>1,887,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,668,141,583</p></td><td><p>1,792,000,000</p></td><td><p>93</p></td></tr></tbody></table><p><sup><br>2</sup>This comprises the fees and allowances paid under Part IIIA: Professional Fees (Pharmacy Contractors) and Part VIA: Payment for Essential Services (Pharmacy Contractors) of the Drug Tariff, and through the Quality Payment Scheme and Pharmacy Access Scheme. This does not include medicines margin.</p><p>Within the NHS Long Term Plan, Government has committed to expanding the number of pharmacists in Primary Care Networks. These pharmacists are well placed to work alongside the wider medical team to optimise the use of medicines, promote medicines adherence and improve the clinical and cost effectiveness of prescribed medications. Identifying and supporting patients on complex polypharmacy and those with long term conditions necessitating repeat prescriptions will form an important part of their role. Alongside this, in August 2018, NHS England, announced plans for a new pilot scheme, with investment of £1 million from the Pharmacy Integration Fund to develop system leadership within pharmacy across all settings. These pharmacy leaders will set the vision to systematically tackle medicines optimisation priorities for the local population within GP Network and Integrated Care System foot prints, further supporting medicines adherence, and in turn reducing medicines wastage.</p><p> </p><p> </p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN
219278 more like this
219279 more like this
219281 more like this
question first answered
less than 2019-02-14T17:46:27.347Zmore like thismore than 2019-02-14T17:46:27.347Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
392
label Biography information for Sir Kevin Barron more like this
1058803
registered interest false more like this
date less than 2019-02-11more like thismore than 2019-02-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Prescription Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps are being taken to (a) increase medicines adherence for repeat prescriptions and (b) reduce medicines wastage from repeat prescriptions. more like this
tabling member constituency Rother Valley more like this
tabling member printed
Sir Kevin Barron more like this
uin 219281 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-14more like thismore than 2019-02-14
answer text <p>The Government has been clear that it wants to change the focus of the health and care system onto prevention and Ministers have also set out an ambition for local pharmacies to play a stronger role in helping people stay well in the community. The Department has committed to publishing a Green Paper on prevention that will set out how these plans will be achieved in more detail. An assessment specifically focusing on the potential merits of nationally commissioning more public health services through community pharmacy has not been undertaken.</p><p>An updated list of the 1,413 pharmacies found to be eligible for the pharmacy access scheme was published in January 2018, this is publicly available and can be found at the following link:</p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf</a></p><p>A small proportion of the pharmacies eligible for the scheme will not receive a payment because they do not meet the payment criteria as set out in the Drug Tariff. This means their income in 2016/17 is greater than their 2015/16 income less a 1% efficiency saving, and/or their estimated income in 2017/18 and 2018/19 is greater than their 2015/16 income less a 3% efficiency saving. The number and proportion of pharmacies on the scheme in receipt of a payment, for each year that the scheme has been running, is set out in the following table.</p><table><tbody><tr><td><p> </p></td><td><p>Total number of eligible pharmacies</p></td><td><p>Total number of pharmacies receiving zero payments</p></td><td><p>Total number of pharmacies in receipt of payment</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,402</p></td><td><p>47 (3%)</p></td><td><p>1,355 (97%)</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,415<sup><sup>[1]</sup></sup></p></td><td><p>57 (4%)</p></td><td><p>1,358 (96%)</p></td></tr></tbody></table><p><sup><sup><br>[1]</sup></sup>Two additional pharmacies have been accepted on to the scheme since the publication of the updated list. This explains the difference in the figures of 1,413 and 1,415 for 2017/18.</p><p>The fees and allowances paid under the Community Pharmacy Contractual Framework (CPCF) for the provision of essential services, including dispensing, provided by community pharmacies each year from April 2015 to March 2018 are detailed in the following table, based on data provided by NHS England. The structure of fees and allowances does not allow payments just for dispensing to be isolated. These payments do not include the medicine margin that community pharmacies earn as part of the payment for essential services, which is paid through reimbursement within the drugs’ bill.</p><p>Enhanced services are locally commissioned. As such they are funded outside of the national CPCF and the Department does not hold the information sought.</p><table><tbody><tr><td><p>Time period</p></td><td><p>Total essential services funding<sup>2</sup> /£</p></td><td><p>Total national CPCF funding (essential and advanced services) less medicines margin/ £</p></td><td><p>Funding for essential services as a proportion of total national CPCF funding (essential and advanced services) less medicines margin/ %</p></td></tr><tr><td><p>2015/16</p></td><td><p>1,881,828,149</p></td><td><p>2,000,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,769,216,586</p></td><td><p>1,887,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,668,141,583</p></td><td><p>1,792,000,000</p></td><td><p>93</p></td></tr></tbody></table><p><sup><br>2</sup>This comprises the fees and allowances paid under Part IIIA: Professional Fees (Pharmacy Contractors) and Part VIA: Payment for Essential Services (Pharmacy Contractors) of the Drug Tariff, and through the Quality Payment Scheme and Pharmacy Access Scheme. This does not include medicines margin.</p><p>Within the NHS Long Term Plan, Government has committed to expanding the number of pharmacists in Primary Care Networks. These pharmacists are well placed to work alongside the wider medical team to optimise the use of medicines, promote medicines adherence and improve the clinical and cost effectiveness of prescribed medications. Identifying and supporting patients on complex polypharmacy and those with long term conditions necessitating repeat prescriptions will form an important part of their role. Alongside this, in August 2018, NHS England, announced plans for a new pilot scheme, with investment of £1 million from the Pharmacy Integration Fund to develop system leadership within pharmacy across all settings. These pharmacy leaders will set the vision to systematically tackle medicines optimisation priorities for the local population within GP Network and Integrated Care System foot prints, further supporting medicines adherence, and in turn reducing medicines wastage.</p><p> </p><p> </p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
grouped question UIN
219278 more like this
219279 more like this
219280 more like this
question first answered
less than 2019-02-14T17:46:27.19Zmore like thismore than 2019-02-14T17:46:27.19Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
392
label Biography information for Sir Kevin Barron more like this
1058809
registered interest false more like this
date less than 2019-02-11more like thismore than 2019-02-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Preventive Medicine more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, when the Government plans to publish the prevention green paper. more like this
tabling member constituency South Shields more like this
tabling member printed
Mrs Emma Lewell-Buck more like this
uin 219457 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-14more like thismore than 2019-02-14
answer text <p>I refer the hon. Member to the answer I gave to the hon. Member for Glasgow Central (Alison Thewliss MP) on 16 January to Question <a href="https://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2019-01-09/206879/" target="_blank">206879</a>.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2019-02-14T12:00:51.247Zmore like thismore than 2019-02-14T12:00:51.247Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4277
label Biography information for Mrs Emma Lewell-Buck more like this
1058810
registered interest false more like this
date less than 2019-02-11more like thismore than 2019-02-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading NHS: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, when each of the NICE methodology reviews for STA and HST are planned (a) to begin, (b) to be consulted upon and (c) to have the findings reported. more like this
tabling member constituency Newton Abbot more like this
tabling member printed
Anne Marie Morris more like this
uin 219448 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-14more like thismore than 2019-02-14
answer text <p>The National Institute for Health and Care Excellence (NICE) is in the process of planning how to conduct its scoping of the review of the methods for technology appraisal and highly specialised technologies evaluations. Scoping will involve industry and other relevant stakeholders, including patient organisations and is timetabled in the 2019/20 business year. Additional detail and more information will be made available on the NICE website in due course.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2019-02-14T17:46:04.073Zmore like thismore than 2019-02-14T17:46:04.073Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4249
label Biography information for Anne Marie Morris more like this